---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-264057"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:37:23.651812+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023

## Summary
- Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.
- Granted option to purchase 75,000 shares at $0.99, vesting over 48 months from Oct 23, 2023.
- Served as Chief Business Officer since May 2022; previously COO of Novosteo Inc.
- No family relationships or transactions requiring disclosure under Item 404(a).

## SEC filing metadata
- accession: 0001193125-23-264057
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/0001193125-23-264057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/d563197d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-264057
- JSON: https://secwatch.observer/filing/0001193125-23-264057.json
- Plain text: https://secwatch.observer/filing/0001193125-23-264057.txt

## Key facts
- Executive change
  Brendan Hannah was appointed as Chief Operating Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. (the “Company”) appointed Brendan Hannah to the position of Chief Operating Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523264057/0001193125-23-264057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.